Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.

ABSTRACT:

Purpose

Zilovertamab vedotin, an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), had manageable safety and promising antitumor activity in participants with relapsed or refractory non-Hodgkin lymphomas. We evaluated zilovertamab vedotin in participants with previously treated metastatic solid tumors.

Patients and methods

This phase 2, open-label, nonrandomized study (NCT04504916) enrolled participants with metastatic triple-negative breast cancer, hormone receptor-positive breast cancer, nonsquamous non-small-cell lung cancer, platinum-resistant ovarian cancer, or pancreatic cancer. Participants received zilovertamab vedotin ≤2.5 mg/kg once every 3 weeks (Q1/3W) or <1.75 mg/kg twice every 3 weeks (Q2/3W). The primary endpoint was obj

SUBMITTER: Meric-Bernstam F 

PROVIDER: S-EPMC12442023 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature